Chemed Research and Development Expenses 2010-2025 | CHE

Chemed annual/quarterly research and development expenses history and growth rate from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Chemed research and development expenses for the quarter ending March 31, 2025 were $0M, a 0% increase year-over-year.
  • Chemed research and development expenses for the twelve months ending March 31, 2025 were $0M, a 0% increase year-over-year.
  • Chemed annual research and development expenses for 2024 were $0B, a 0% decline from 2023.
  • Chemed annual research and development expenses for 2023 were $0B, a 0% decline from 2022.
  • Chemed annual research and development expenses for 2022 were $0B, a 0% decline from 2021.
Chemed Annual Research and Development Expenses
(Millions of US $)
2024 $0
2023 $0
2022 $0
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $0
2013 $0
2012 $0
2011 $0
2010 $0
2009 $0
Chemed Quarterly Research and Development Expenses
(Millions of US $)
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $8.501B $2.431B
Chemed Corporation purchases, operates and divests subsidiaries engaged in diverse business activities. The company's operating businesses are managed on a decentralized basis. Chemed currently operates as two wholly-owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS Healthcare segment provides hospice and palliative care services for patients with terminal illnesses. VITAS offer all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Roto-Rooter segment provides plumbing and drain-cleaning services to both residential and commercial customers. It provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service marks. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations.
Stock Name Country Market Cap PE Ratio
Quest Diagnostics (DGX) United States $18.282B 18.36
DaVita (DVA) United States $11.202B 14.29
Encompass Health (EHC) United States $10.408B 23.33
Option Care Health (OPCH) United States $5.259B 25.21
Elanco Animal Health (ELAN) United States $4.190B 9.27
RadNet (RDNT) United States $3.686B 79.02
Amedisys (AMED) United States $3.011B 21.29
LifeStance Health (LFST) United States $2.576B 0.00
Addus HomeCare (ADUS) United States $1.840B 21.32
Astrana Health (ASTH) United States $1.573B 35.26
U.S Physical Therapy (USPH) United States $1.025B 26.14
Pennant (PNTG) United States $0.907B 36.29
Aveanna Healthcare Holdings (AVAH) United States $0.886B 0.00
Atai Life Sciences (ATAI) Germany $0.294B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.006B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
Psychemedics (PMD) United States $0.000B 0.00